Today’s guest is Edmund Ben-Ami, CEO of NeuraLight — the company using AI and a simple webcam to radically improve how neurological diseases are measured.

NeuraLight’s eye-tracking technology is already being deployed in clinical trials, where it has shown the ability to be up to 10× more sensitive than existing neurological assessment tools.

In this conversation, we explore how AI-driven biomarkers are reshaping neurology, the realities of working with pharma and clinical trial teams, and what it takes to build and scale a scientifically rigorous healthtech company.

This episode is a deep dive into where AI meets neuroscience, and why better data could change patient outcomes at scale.

🎯 Key Topics Covered

The original vision behind NeuraLight and how it has evolved

Balancing scientific rigour with commercial scale in healthtech

How pharma and clinical trial teams are using NeuraLight today

The realities of deploying AI inside hospitals and trials

What “success” looks like in neurological biomarkers over the next 3–5 years